JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sanjay, O. P.
Right arrow Articles by Tauro, D. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanjay, O. P.
Right arrow Articles by Tauro, D. I.
Related Collections
Right arrow Surgery
Right arrow Postanesthetic Care Unit
Right arrow Cardiovascular
Right arrow Heart
Right arrow Pharmacology

Anesth Analg 2004;99:339-343
© 2004 International Anesthesia Research Society
doi: 10.1213/01.ANE.0000121772.29181.71

CARDIOVASCULAR ANESTHESIA

Midazolam: An Effective Antiemetic After Cardiac Surgery—A Clinical Trial

Orathy Patangi Sanjay, MD, and Deepak Ivan Tauro, MBBS

Department of Anesthesiology, St. John’s Medical College Hospital, Bangalore, Karnataka, India

Address correspondence to Orathy Patangi Sanjay, MD, DNB, DA, Department of Anesthesiology, St. John’s Medical College Hospital, Bangalore 560034, Karnataka, India. Address e-mail to sanjaysanjay_op{at}rediffmail.com Reprints will not be available from the authors.

Cardiac surgery has been associated with a significant incidence of postoperative nausea and vomiting (PONV). To assess the antiemetic property of midazolam, we undertook this double-blinded, randomized trial in 200 patients undergoing cardiac surgery involving cardiopulmonary bypass, and we compared its efficacy with that of ondansetron in preventing PONV. Assessments on the occurrence of PONV were made at regular intervals for the first 24 h after tracheal extubation, along with sedation and pain scoring. We report a 6% incidence of nausea and no incidence of vomiting in the midazolam group, compared with a 21% incidence of PONV in the ondansetron group (P < 0.001). All 21 patients (18 women and 3 men) in the ondansetron group and none of the 6 patients (all women) in the midazolam group required a rescue antiemetic drug (P < 0.001). The sedation scores and postoperative pain scores were comparable in both groups. We conclude that midazolam, instituted as a continuous infusion in a dose of 0.02 mg · kg–1 · h–1, is a more effective antiemetic than ondansetron in a dose of 0.1 mg/kg IV every 6 h for the prevention of PONV after cardiac surgery.

IMPLICATIONS: Midazolam is a more effective antiemetic than ondansetron for preventing postoperative nausea and vomiting after cardiac surgery.






Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 2004 by the International Anesthesia Research Society.